Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolinza in Metastatic Breast Cancer
NCT00132002Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2005
- Primary completion
- Jan 2008
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in breast cancer, sponsored by National Cancer Institute. Started Jun 2005; status: terminated.
02
Drugs
vorinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00132002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132002.